Clinical Exploration of Tegio Capsules in Palliative Treatment of Late-Stage Gastrointestinal Tumors
Objective To explore the clinical application of Tegio capsules in palliative treatment of late-stage gastrointestinal tumors.Methods 68 patients with late-stage gastrointestinal tumors treated in The First Affiliated Hospital of Henan University from October 2022 to April 2024 were selected as the research subjects.They were divided into a routine group and a research group,each with 34 cases,according to the random number table method.The routine group patients received routine palliative treatment,and the research group patients took Tegio capsules on the basis of palliative treatment.The treatment effects of the two groups of patients and the levels of vascular endothelial growth factor(VEGF)and tumor abnormal protein(TAP)agglomerate area were evaluated,and the occurrence of adverse reactions in the two groups of patients was statistically compared.Results After two courses of treatment,the effective rate of treatment in the research group was higher than that in the routine group,and the difference was statistically significant(P＜0.05).The incidence of adverse reactions in the research group was lower than that in the routine group,and the difference was statistically significant(P＜0.05).After treatment,the VEGF level and TAP agglomerate area of the research group patients were lower than those of the routine group,and the difference was statistically significant(P＜0.05).Conclusion The reasonable use of Tegio capsules in the palliative treatment plan for patients with late-stage gastrointestinal tumors can improve the tumor control rate,help reduce the incidence of adverse reactions in patients,and the detection of VEGF and TAP can help understand the treatment effect of patients,which is worth applying.
万方数据
维普
